Innocan Pharma Corporation reported a 433% year-over-year revenue increase for fiscal 2023, totaling $13.6 million. This growth is attributed to strong sales from its subsidiary, B.I. Sky Global Ltd. Innocan is also pursuing FDA approval for its human pharmaceutical applications, with pre-investigational new drug applications expected to be submitted soon. The company's LPT platform, which involves injectable CBD encapsulated in liposomes, has shown promising results in pre-clinical trials for chronic pain and drug-resistant epileptic seizures.